Skip to main content

Table 1 Demographics and baseline characteristics of the prior AMPH subgroup (n = 41) and overall safety population (n = 420)

From: Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study

Variable, n (%) Prior AMPH subgroup Overall safety population
Placebo LDX (all doses) Placebo LDX (all doses)
n = 2 n = 39 n = 62 n = 358
Sex Male 0 20 (51.3) 32 (51.6) 196 (54.7)
Female 2 (100.0) 19 (48.7) 30 (48.4) 162 (45.3)
Race White 1 (50.0) 38 (97.4) 48 (77.4) 301 (84.1)
Non-white 1 (50.0) 1 (2.6) 14 (22.6) 57(15.9)
Ethnicity Hispanic/Latino 0 1 (2.6) 6 (9.7) 34 (9.5)
Non-Hispanic/Non-Latino 2 (100.0) 38 (97.4) 56 (90.3) 324 (90.5)
CGI-S at baseline Moderately ill 1 (50.0) 12 (30.8) 27 (43.5) 115 (32.1)
Markedly ill 1 (50.0) 17 (43.6) 25 (40.3) 195 (54.5)
Severely/extremely ill 0 10 (25.6) 10 (16.1) 48 (13.4)